CYCLOPHOSPHAMIDE, ADRIAMYCIN, METHOTREXATE, AND PROCARBAZINE (CAMP)-EFFECTIVE 4-DRUG COMBINATION CHEMOTHERAPY FOR METASTATIC NON-OAT CELL BRONCHOGENIC CARCINOMA
- 1 January 1976
- journal article
- research article
- Vol. 60 (9) , 1225-1230
Abstract
Twenty-three patients with metastatic non-oat cell bronchogenic carcinoma (MNOBC) were treated with cyclophosphamide, adriamycin, methotrexate and procarbazine (CAMP) after radiation therapy. Objective responses were seen in 11 of 23 patients (48%) with a projected median survival time of 12.5 mo. for responding patients and patients with stable disease. Lung, liver and cutaneous sites of involvement were highly responsive; bone involvement was less responsive. CAMP is an effective combination in the treatment of MNOBC and its use in patients with less advanced disease should be explored.This publication has 3 references indexed in Scilit:
- Bacon (bleomycin, adriamycin, CCNU, oncovin and nitrogen mustard) in squamous lung cancer. Experience in fifty patientsCancer, 1976
- BLEOMYCIN (NSC-125066) FOLLOWED BY CYCLOPHOSPHAMIDE (NSC-26271), VINCRISTINE (NSC-67574), METHOTREXATE (NSC-740), AND 5-FLUOROURACIL (NSC-19893) FOR NON-OAT CELL BRONCHOGENIC CARCINOMA1976
- Cell Type and the Natural History of Lung CancerJAMA, 1965